- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05248555
O Programa Nacional Australiano de Testes Point-of-Care para VHC - Conjunto de Dados Mínimo
O Programa Nacional Australiano de Testes Point-of-Care para HCV: Um Estudo de Coorte Observacional para Avaliar o Uso de Testes de Hepatite C Point-of-Care por Picada no Dedo para Melhorar o Diagnóstico e o Tratamento da Infecção por HCV - Conjunto de Dados Mínimo
The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). All participants who undergo HCV point-of-care testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The advent of simple direct-acting antiviral hepatitis C (HCV) therapies with cure rates >95% is one of the greatest medical advances in decades, having led to a reversal in liver-related mortality. In Australia, treatment uptake has declined between 2016 (32,000 treated) and 2019/20 (2019: 11,500; 2020: 8,500).1 Progress towards HCV elimination has been impeded by COVID-19, affecting the delivery of national and state-based HCV strategies. Improving HCV treatment uptake to reduce disease burden is a key aim of global, national and state-based HCV strategies.2-4
Scale-up of HCV testing and treatment will be required to achieve elimination by 2030. Current diagnostic pathways require multiple visits to a practitioner reducing the proportion who receive a diagnosis. In Australia, 81% of people have had HCV antibody testing (indicates exposure), but only 47% have been HCV RNA tested (indicates active infection and the need for HCV treatment).5 Mathematical modelling suggests that HCV RNA testing needs to increase by at least 50% annually to achieve elimination in Australia by 2030.6
The Kirby Institute is an international leader in research evaluating the Xpert HCV assay (Grebely Lancet Gastro Hep 2017), having built a large network of Xpert platforms for HCV testing in needle and syringe programs, prisons, drug treatment clinics, tertiary hospitals, and Aboriginal Community Controlled Health Service. In Kirby-led research, point-of-care HCV testing interventions in needle and syringe programs and prisons have resulted in high HCV treatment uptake (70-90%). The Kirby Institute and Flinders University also have a strong track record of implementing point-of-care testing for STIs and COVID-19, providing an ideal foundation to scale-up Xpert HCV testing in Australia.
The Kirby Institute and Flinders University will establish the Australian National HCV Point-of-care Testing Program for the scale-up of point-of-care HCV RNA testing in services with high prevalence of HCV infection, including community health centres, drug treatment clinics, needle and syringe programs, and prisons. This program will include the development of standard operating procedures, logistics/deployment, initial set-up, an operator training program, and quality assurance and competency assessment program.
An observational cohort study will be established to evaluate HCV treatment uptake following scale-up of point-of-care HCV testing among people with a risk factor for acquisition of HCV infection or people attending a service caring for people with risk factors for the acquisition of HCV infection.
Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection. All participants who undergo point-of-care HCV testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care for any other clinical assessments and treatment initiation.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Simon Comben, BSc, MN
- Número de telefone: +6193480777
- E-mail: scomben@kirby.unsw.edu.au
Estude backup de contato
- Nome: David Silk, BSc
- Número de telefone: +61293850900
- E-mail: dsilk@kirby.unsw.edu.au
Locais de estudo
-
-
New South Wales
-
Sydney, New South Wales, Austrália
- Ativo, não recrutando
- Justice Health and Forensic Mental Health Network
-
-
Queensland
-
Aldershot, Queensland, Austrália, 4650
- Recrutamento
- Maryborough Correctional Centre
-
Contato:
- Ashley Willman
- Número de telefone: (07) 4123 7600
- E-mail: ashley.willmann@health.qld.gov.au
-
Brisbane, Queensland, Austrália, 4000
- Recrutamento
- QuIHN
-
Contato:
- Nicholas Alexander
- Número de telefone: 3620 8111
- E-mail: nalexander@quihn.org
-
Cairns, Queensland, Austrália
- Recrutamento
- Lotus Glen Correctional Centre
-
Contato:
- Darren Russell
-
Investigador principal:
- Darren Russell
-
Coorparoo, Queensland, Austrália, 4151
- Concluído
- Hepatitis Queensland
-
Ipswich, Queensland, Austrália
- Recrutamento
- West Moreton Hospital and Health Service
-
Contato:
- Blake Ponting
-
Investigador principal:
- Blake Ponting
-
Rathdowney, Queensland, Austrália, 4287
- Ainda não está recrutando
- Palen Creek Correctional Centre
-
Contato:
- Mike Hurley
- Número de telefone: (07) 5544 3700
- E-mail: mike.hurley@corrections.qld.gov.au
-
Townsville, Queensland, Austrália
- Recrutamento
- Townsville Correctional Centre
-
Contato:
- John Morey
-
Investigador principal:
- John Morey
-
Woodford, Queensland, Austrália
- Recrutamento
- Woodford Correctional Centre
-
Contato:
- Rajendra Prakash
-
Investigador principal:
- Rajendra Prakash
-
-
South Australia
-
Hackney, South Australia, Austrália, 5069
- Recrutamento
- Hepatitis SA
-
Contato:
- Lisa Carter
- Número de telefone: (08) 8362 8443
- E-mail: lisa@hepatitissa.asn.au
-
Marden, South Australia, Austrália, 5070
- Ainda não está recrutando
- South Australian Prison Health Service
-
Contato:
- Tom Turnbull
-
Investigador principal:
- Tom Turnbull
-
Mount Gambier, South Australia, Austrália, 5290
- Recrutamento
- Mount Gambier Priosn
-
Contato:
- William Galloway
-
Investigador principal:
- William Galloway
-
-
Victoria
-
Fitzroy, Victoria, Austrália, 3065
- Ativo, não recrutando
- St Vincent's Correctional Health Services
-
Melbourne, Victoria, Austrália, 3000
- Recrutamento
- Medically Supervised Injecting Room
-
Contato:
- Nathan Stam
-
Investigador principal:
- Nathan Stam
-
Ravenhall, Victoria, Austrália, 3023
- Recrutamento
- Dame Phyllis Frost Centre
-
Contato:
- Katelyn Mannix
- Número de telefone: 1300 492 202
- E-mail: katelyn.mannix@wh.org.au
-
Ravenhall, Victoria, Austrália, 3023
- Recrutamento
- Geo Healthcare - The Geo Group Australia Pty Ltd
-
Contato:
- David Grace
-
Investigador principal:
- David Grace
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection, including drug treatment clinics, needle and syringe programs, prisons, mobile outreach services, community health services, mental health services, homelessness services, and other appropriate settings nationally. It is anticipated approximately 40,000 participants will be screened for HCV infection using point-of-care HCV testing.
Descrição
Inclusion Criteria:
- ≥ 18 years of age.
- Received point-of-care HCV testing.
Exclusion Criteria:
- Nil
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
People at risk of HCV acquisition
Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing. |
Participants will be offered finger-stick point-of-care testing for HCV |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The proportion of HCV infected participants who initiate HCV treatment at 12 weeks
Prazo: 12 Weeks from enrolment
|
To evaluate the proportion of HCV infected (HCV RNA quantifiable) participants who initiate HCV treatment at 12 weeks following finger-stick point-of-care HCV RNA testing. |
12 Weeks from enrolment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The proportion of participants who accept point-of-care testing
Prazo: 2 years from recruitment commencement
|
To evaluate the proportion of people who accept point-of-care testing among those offered testing. |
2 years from recruitment commencement
|
|
The prevalence of HCV infection amongst study participants tested
Prazo: 2 years from recruitment commencement
|
To evaluate the prevalence of current HCV infection (HCV RNA quantifiable) among people tested. |
2 years from recruitment commencement
|
|
To evaluate the time to HCV treatment uptake among HCV RNA positive participants
Prazo: 52 weeks
|
To evaluate the length of time participants take to initiate HCV treatment after diagnosis |
52 weeks
|
|
To evaluate proportion of HCV RNA positive participants who initiate HCV treatment
Prazo: 52 weeks
|
To evaluate the proportion of HCV RNA positive participants who initiate HCV treatment at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing. |
52 weeks
|
|
To evaluate the proportion of participants who complete HCV (DAA) treatment
Prazo: 52 weeks
|
To evaluate the proportion of participants who complete HCV direct-acting antiviral (DAA) treatment. |
52 weeks
|
|
To evaluate the proportion of participants who achieve an SVR
Prazo: 12 weeks
|
To evaluate the proportion of participants who achieve an SVR (defined as HCV RNA below the lower limit of quantitation at post treatment week 12). |
12 weeks
|
|
To evaluate the proportion of participants who are HCV RNA negative at 12 months
Prazo: 52 weeks
|
To evaluate the proportion of participants who are HCV RNA negative at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing. |
52 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- VHCRP2104
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Request to share IPD will be considered by the protocol steering committee on individual basis
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .